Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198

Active Not RecruitingPhase 2

Sponsor: Corcept Therapeutics

Conditions: Cushing Syndrome

Interventions: relacorilant

Countries: United States, Austria, Canada, Germany, Israel, Italy, Netherlands, Poland

This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Major Inclusion Criteria:

  * Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome
  * According to the Investigator's opinion will benefit from continuing treatment with relacorilant.

Exclusion Criteria:

* Major Exclusion Criteria:

  * Premature discontinuation from a relacorilant parent study
  * Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
Locations (48)
  • Phoenix, Arizona, United States
  • Stanford, California, United States
  • Torrance, California, United States
  • Miami, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Metairie, Louisiana, United States
  • Baltimore, Maryland, United States
  • Fall River, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Rochester, Minnesota, United States
  • Jackson, Mississippi, United States
  • St Louis, Missouri, United States
  • Reno, Nevada, United States
  • Albany, New York, United States
  • New York, New York, United States
  • Wilmington, North Carolina, United States
  • Cleveland, Ohio, United States
  • Pittsburgh, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Dallas, Texas, United States
  • El Paso, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Vienna, Austria
  • Nova Scotia, Canada
  • Munich, Germany
  • Würzburg, Germany
  • Ramat Gan, Israel
  • + 18 more on CT.gov